Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Convertible Preferred Stock and Changes in Stockholders??? (Deficit) Equity (Unaudited)

v3.21.1
Condensed Consolidated Statements of Convertible Preferred Stock and Changes in Stockholders’ (Deficit) Equity (Unaudited) - USD ($)
Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Total
Balance at Dec. 31, 2019 $ 53,882,460 $ 83 $ 3,174,102 $ (68,274,256) $ (41,400) $ (65,141,471)
Balance (in Shares) at Dec. 31, 2019 14,639,043 833,505        
Issuance of Series B convertible preferred stock, net of issuance costs $ 400,504    
Issuance of Series B convertible preferred stock, net of issuance costs (in Shares) 173,752          
Exercise of common stock options   1,646 1,646
Exercise of common stock options (in Shares) 1,924        
Stock-based compensation expense 97,308 97,308
Foreign currency translation adjustment (705) (705)
Net loss (4,738,346) (4,738,346)
Balance at Mar. 31, 2020 $ 54,282,964 $ 83 3,273,056 (73,012,602) (42,105) (69,781,568)
Balance (in Shares) at Mar. 31, 2020 14,812,795 835,429        
Balance at Dec. 31, 2020 $ 2,686 87,051,058 (83,877,972) (52,162) 3,123,610
Balance (in Shares) at Dec. 31, 2020 26,859,850        
Issuance of common stock warrants 395,412 395,412
Issuance of common stock in connection with exercise of warrants 3,619 3,619
Issuance of common stock in connection with exercise of warrants (in Shares) 4,208        
Stock-based compensation expense 384,407 384,407
Foreign currency translation adjustment 3,530 3,530
Net loss (4,904,196) (4,904,196)
Balance at Mar. 31, 2021 $ 2,686 $ 87,834,496 $ (88,782,168) $ (48,632) $ (993,618)
Balance (in Shares) at Mar. 31, 2021 26,864,058